FoldRx touts tafamidis data

FoldRx Pharmaceuticals announced that the Phase II/III study for tafamidis demonstrates that the drug "significantly halts disease progression for patients with a disease called Transthyretin-TTR--amyloid polyneuropathy." FoldRx co-founder Jeffery Kelly, Ph.D., said that "this is the first pharmacologic evidence that the biomedical researcher communities' hypothesis about the etiology of human amyloid diseases, including Alzheimer's disease, is likely correct. The development of tafamidis--the first disease-modifying agent targeting the underlying cause of a human amyloid disease--was built on years of basic scientific research, funded by institutions including the National Institutes of Health, the Skaggs Institute for Chemical Biology, and The Lita Annenberg Hazen Foundation." Release